This HTML5 document contains 75 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
dbohttp://dbpedia.org/ontology/
foafhttp://xmlns.com/foaf/0.1/
n12https://global.dbpedia.org/id/
dbthttp://dbpedia.org/resource/Template:
rdfshttp://www.w3.org/2000/01/rdf-schema#
n17http://adisinsight.springer.com/drugs/
n16http://www.ontologydesignpatterns.org/ont/dul/DUL.owl#
n13http://commons.wikimedia.org/wiki/Special:FilePath/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
wikipedia-enhttp://en.wikipedia.org/wiki/
dbchttp://dbpedia.org/resource/Category:
dbphttp://dbpedia.org/property/
provhttp://www.w3.org/ns/prov#
xsdhhttp://www.w3.org/2001/XMLSchema#
wikidatahttp://www.wikidata.org/entity/
dbrhttp://dbpedia.org/resource/

Statements

Subject Item
dbr:Relacorilant
rdf:type
dbo:Drug wikidata:Q8386 owl:Thing n16:ChemicalObject dbo:ChemicalSubstance
rdfs:label
Relacorilant
rdfs:comment
Relacorilant (developmental code name CORT-125134) is an antiglucocorticoid which is under development by Corcept Therapeutics for the treatment of Cushing's syndrome. It is also under development for the treatment of solid tumors and alcoholism. The drug is a nonsteroidal compound and acts as an antagonist of the glucocorticoid receptor. As of December 2017, it is in phase II clinical trials for Cushing's syndrome and phase I/II clinical studies for solid tumors, while the clinical phase for alcoholism is unknown.
foaf:depiction
n13:Relacorilant.svg
dcterms:subject
dbc:Sulfonamides dbc:Pyridines dbc:Experimental_drugs dbc:Ketones dbc:Pyrazoles dbc:Antiglucocorticoids dbc:Trifluoromethyl_compounds dbc:Fluoroarenes dbc:Isoquinolines
dbo:wikiPageID
56104974
dbo:wikiPageRevisionID
1084240921
dbo:wikiPageWikiLink
dbr:Alcoholism dbr:Oral_administration dbr:Chemical_compound dbc:Pyridines dbc:Experimental_drugs dbr:Cushing's_syndrome dbr:Phases_of_clinical_research dbc:Pyrazoles dbr:Glucocorticoid_receptor dbr:Antiglucocorticoid dbr:Tumor dbc:Ketones dbc:Fluoroarenes dbc:Trifluoromethyl_compounds dbr:Nonsteroidal dbr:Receptor_antagonist dbc:Isoquinolines dbc:Sulfonamides dbc:Antiglucocorticoids dbr:Clinical_trial
dbo:wikiPageExternalLink
n17:800041622
owl:sameAs
n12:4XLxg wikidata:Q48845466
dbp:wikiPageUsesTemplate
dbt:Systemic-hormonal-drug-stub dbt:Glucocorticoid_receptor_modulators dbt:Short_description dbt:Reflist dbt:Drugbox
dbo:thumbnail
n13:Relacorilant.svg?width=300
dbp:c
27
dbp:casNumber
1496510
dbp:chemspiderid
57617720
dbp:class
dbr:Antiglucocorticoid
dbp:f
4
dbp:h
22
dbp:iupacName
[-1--6-sulfonyl-4,5,7,8-tetrahydropyrazolo[3,4-g]isoquinolin-4a-yl]-[4-pyridin-2-yl]methanone
dbp:kegg
D11336
dbp:n
6
dbp:o
3
dbp:pubchem
73051463
dbp:routesOfAdministration
dbr:Oral_administration
dbp:s
1
dbp:smiles
CN1C=CSN2CCC3=CC4=CC=NN4C6=CC=CF
dbp:stdinchi
1
dbp:stdinchikey
WANIDIGFXJFFEL-SANMLTNESA-N
dbp:synonyms
CORT-125134
dbp:unii
2158753
dbo:abstract
Relacorilant (developmental code name CORT-125134) is an antiglucocorticoid which is under development by Corcept Therapeutics for the treatment of Cushing's syndrome. It is also under development for the treatment of solid tumors and alcoholism. The drug is a nonsteroidal compound and acts as an antagonist of the glucocorticoid receptor. As of December 2017, it is in phase II clinical trials for Cushing's syndrome and phase I/II clinical studies for solid tumors, while the clinical phase for alcoholism is unknown.
prov:wasDerivedFrom
wikipedia-en:Relacorilant?oldid=1084240921&ns=0
dbo:wikiPageLength
3454
dbo:casNumber
1496510-51-0
dbo:fdaUniiCode
2158753C7E
dbo:kegg
D11336
dbo:pubchem
73051463
dbo:class
dbr:Antiglucocorticoid
foaf:isPrimaryTopicOf
wikipedia-en:Relacorilant